• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.08% Nasdaq Up0.22%

    More On AEZS

    Aeterna Zentaris Inc. (AEZS)

    11.06 Down 0.37(3.24%) Nov 27, 1:00PM EST
    ProfileGet Profile for:
    Aeterna Zentaris Inc.
    1405 du Parc-Technologique Boulevard
    Quebec City, QC G1P 4P5
    Canada - Map
    Phone: 418-652-8525
    Fax: 418-948-9191
    Website: http://www.aezsinc.com

    Index Membership:N/A
    Full Time Employees:56

    Business Summary 

    Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company’s product pipeline includes MACRILEN, which completed the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Quebec City, Canada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Aeterna Zentaris Inc.

    Key Executives 
    Mr. David Alan Dodd , 65
    Chairman, Chief Exec. Officer and Pres
    Mr. Keith Santorelli CPA,
    Chief Accounting Officer and VP of Fin.
    Dr. Richard Sachse M.D., Ph.D.,
    Chief Scientific Officer, Chief Medical Officer and Sr. VP
    Mr. Jude Dinges ,
    Chief Commercial Officer and Sr. VP
    Mr. Philip A. Theodore , 62
    Chief Admin. Officer, Sr. VP, Gen. Counsel and Corp. Sec.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.